Principal Financial Group Inc Akebia Therapeutics, Inc. Transaction History

Principal Financial Group Inc

  • $184 Billion
  • Q3 2025

A detailed history of Principal Financial Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 226,613 shares of AKBA stock, worth $385,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares
226,613
Previous 16,949 1237.03%
Holding current value
$385,242
Previous $61,000 901.64%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025
BUY
$2.7 - $4.01 $566,092 - $840,752
209,664 Added 1237.03%
226,613 $611,000
Q2 2025

Aug 08, 2025
BUY
$1.55 - $3.97 $4,079 - $10,449
2,632 Added 18.38%
16,949 $61,000
Q1 2025

Apr 28, 2025
BUY
$1.69 - $2.84 $3,542 - $5,952
2,096 Added 17.15%
14,317 $27,000
Q4 2024

Jan 31, 2025
BUY
$1.26 - $2.13 $15,398 - $26,030
12,221 New
12,221 $22,000
Q3 2024

Oct 31, 2024
SELL
$0.94 - $1.55 $5,015 - $8,270
-5,336 Reduced 25.27%
15,777 $20,000
Q2 2024

Jul 29, 2024
BUY
$0.86 - $1.63 $18,157 - $34,414
21,113 New
21,113 $21,000
Q3 2022

Nov 09, 2022
SELL
$0.3 - $0.46 $75,109 - $115,167
-250,364 Reduced 60.42%
164,028 $52,000
Q2 2022

Aug 10, 2022
BUY
$0.32 - $0.67 $73,424 - $153,733
229,453 Added 124.07%
414,392 $146,000
Q1 2022

May 09, 2022
SELL
$0.72 - $2.93 $53,009 - $215,718
-73,624 Reduced 28.47%
184,939 $132,000
Q4 2021

Feb 09, 2022
SELL
$2.26 - $3.34 $635,667 - $939,438
-281,269 Reduced 52.1%
258,563 $584,000
Q3 2021

Nov 09, 2021
SELL
$2.35 - $3.88 $18,884 - $31,179
-8,036 Reduced 1.47%
539,832 $1.55 Million
Q2 2021

Aug 10, 2021
SELL
$2.83 - $4.2 $71,794 - $106,549
-25,369 Reduced 4.43%
547,868 $2.08 Million
Q1 2021

May 10, 2021
BUY
$2.92 - $5.06 $105,365 - $182,585
36,084 Added 6.72%
573,237 $1.94 Million
Q4 2020

Feb 08, 2021
BUY
$2.22 - $3.78 $894,384 - $1.52 Million
402,876 Added 300.03%
537,153 $1.5 Million
Q3 2020

Nov 06, 2020
BUY
$2.39 - $13.08 $97,375 - $532,918
40,743 Added 43.56%
134,277 $337,000
Q2 2020

Aug 05, 2020
BUY
$6.67 - $13.58 $420,210 - $855,540
63,000 Added 206.33%
93,534 $1.27 Million
Q1 2020

May 12, 2020
BUY
$4.1 - $10.24 $54,050 - $134,993
13,183 Added 75.98%
30,534 $231,000
Q4 2019

Feb 05, 2020
SELL
$3.16 - $6.73 $34,914 - $74,359
-11,049 Reduced 38.9%
17,351 $110,000
Q3 2019

Nov 13, 2019
BUY
$3.55 - $5.4 $37,370 - $56,845
10,527 Added 58.9%
28,400 $111,000
Q2 2019

Aug 12, 2019
BUY
$4.1 - $8.05 $27,322 - $53,645
6,664 Added 59.45%
17,873 $87,000
Q1 2019

May 10, 2019
SELL
$5.41 - $8.73 $8,618 - $13,906
-1,593 Reduced 12.44%
11,209 $92,000
Q4 2018

Feb 14, 2019
BUY
$5.39 - $9.15 $69,002 - $117,138
12,802 New
12,802 $71,000

Others Institutions Holding AKBA

# of Institutions
191
Shares Held
121M
Call Options Held
267K
Put Options Held
280K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $313M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email